Latest Publications

Share:

Life Sciences Deals: Hot Topics in 2018 (PowerPoint Slides)

Life science companies operate in a heavily regulated environment and the rules of the game are constantly changing. Join members of Pepper’s Health Sciences Department as they discuss the latest in deals in the life sciences...more

10/2/2018  /  Life Sciences

Life Science Deals: Hot Topics in 2018 [Video]

Life science companies operate in a heavily regulated environment and the rules of the game are constantly changing. Join members of Pepper’s Health Sciences Department as they discuss the latest in deals in the life sciences...more

10/2/2018  /  Life Sciences

SCOTUS Holds Inter Partes Review Proceedings Valid In “Narrow” Decision

This week the Supreme Court of the United States (“Supreme Court”), in a 7-2 decision, held that inter partes review (“IPR”) proceedings conducted by the Patent Trial and Appeal Board (PTAB) do not violate Article III or...more

First AIA Derivation Trial Instituted By PTAB

On March 21, 2018, the Patent Trial and Appeal Board (“PTAB”) instituted the first AIA derivation proceeding to determine whether patent claims to a window frame component should be canceled because they were derived from...more

NIH May Own Gilead's Blockbuster Hepatitis Drug Due to Misstep

Every year, the National Institutes of Health (NIH) spends billions of federal dollars on research and development of new drugs and therapies for treating and preventing serious illnesses....more

Deuterated Drugs Are New Chemical Entities

FDA recently awarded new chemical entity (NCE) exclusivity to Austedo™ (deutetrabenazine). The Austedo approval is notable for two reasons: One, it is the first deuterated drug (i.e., a drug containing the stable isotope —...more

FDA Is Evolving on Qualifications for 'New Chemical Entity'

The prior approval of a drug containing an active ingredient of the innovator drug is not necessarily a death knell for NCE exclusivity. Originally published in the Intellectual Property and Life Sciences sections of...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide